PY
PYCXF.US PYC Therapeutics Limited
- Market cap
- USD 1.20B
- P/E
- -
- P/B
- 2.56x
- ROE
- -6.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is PYCXF.US undervalued?
Graham numberThe Graham number of PYC Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PYC Therapeutics Limited fundamental analysis
No fundamental analysis for PYC Therapeutics Limited yet.
PYC Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PYC Therapeutics Limited
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic …
Full company profilePYC Therapeutics Limited financial statements
PYC Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating Income | -30.2M | -39.2M | -60.4M | -75.9M | -82.7M |
| EBITDA | - | -22.8M | -37.5M | -50.4M | -43.1M |
| Net Income | -13.9M | -22.8M | -37.7M | -50.3M | -43.3M |
| EPS | -0.04 | -0.06 | -0.08 | -0.08 | -0.04 |
| Balance Sheet | |||||
| Total Assets | 45.4M | 37.2M | 91.2M | 183M | 709M |
| Total Liabilities | 5.15M | 8.72M | 10.2M | 13.3M | 15.2M |
| Shareholders' Equity | 39.4M | 27.7M | 80.5M | 170M | 693M |
| Cash & Short-term Investments | 29.1M | 15.6M | 66.9M | 153M | 53.6M |
| Cash Flow | |||||
| Capital Expenditure | 387K | 491K | 307K | 975K | 531K |
| Free Cash Flow | -22.2M | -24.9M | -38.9M | -52.5M | -45.1M |
| Ratios | |||||
| ROE | -35.2% | -82.1% | -46.9% | -29.7% | -6.3% |
| ROA | -30.6% | -61.3% | -41.3% | -27.4% | -6.1% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
PYC Therapeutics Limited dividends
PYC Therapeutics Limited has not paid dividends in the last 5 fiscal years.
Who owns PYC Therapeutics Limited
- Insiders 33.82%
- Institutions 20.22%
- Public & others 45.97%
- Shares outstanding 985M
- Free float 618M
PYC Therapeutics Limited company profile
- Company name
- PYC Therapeutics Limited
- Ticker
- PYCXF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009
- Phone
- 61 8 6151 0992
- Website
- pyctx.com
About PYC Therapeutics Limited
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
PYC Therapeutics Limited management
8- Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Executive Director · born 1983
- Mr. Thomas UlmerChief Financial Officer · born 1978
- Dr. Garrett BrayChief Operating Officer
- Dr. Janya GrainokChief Scientific Officer
- Mr. Jonathan Riley B.Sc., L.L.B.General Counsel & Joint Company Secretary
- Dr. Paula CunninghamChief Development Officer
- Ms. Candice JungeChief Clinical Development Officer
- Mr. Stephen Alan Ledger B.Com.Joint Company Secretary